Abstract
Type 1 diabetes mellitus is potentially associated with serious microvascular and macrovascular complications, although these are usually subclinical during the pediatric and adolescent years. There is no “grace” period for the beginnings of such complications. Duration of diabetes, glycemic control, age, and pubertal stage are critical factors contributing toward development of such problems. Other risk factors include family history (genetic predisposition), hyperlipidemia, hypertension, and smoking. The Diabetes Control and Complications Trial (DCCT) proved the importance of glycemic control and emphasized the ability of improved glucose control to prevent or decrease retinopathy, nephropathy, and neuropathy using a multidisciplinary same-philosophyof-care approach plus targeted glucose and hemoglobin A1c values. Other natural history and intervention studies support the findings of the DCCT. Although our current tools are not perfect, they allow us to decrease microangiopathic complications very significantly if we educate our patients and their family members. Metabolic control counts.
Similar content being viewed by others
References and Recommended Reading
DCCT Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus: The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993, 329:977–986.
DCCT Research Group: Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: Diabetes Control and Complications Trial: Diabetes Control and Complications Trial Research Group. J Pediatr 1994, 125:177–188.
Ahern JA, Wesche J, Strand T, et al.: The impact of the trial coordinator in the Diabetes Control and Complications Trial (DCCT): The DCCT Research Group. Diabetes Educ 1993, 19:509–512.
Brink SJ: How to apply the experience from the diabetes control and complications trial to children and adolescents? Ann Med 1997, 29:425–438.
DCCT/Epidemiology of Diabetes Interventions and Complications Research Group: Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy: The Diabetes Control and Complications Trial/ Epidemiology of Diabetes Interventions and Complications Research Group. N Engl J Med 2000, 342:381–389. This article documents intent-to-treat analysis improvement even 4 years after the end of the formal DCCT. It suggests that many years of improved glycemic control continue to matter 4 years after the study ended. The two groups’ glucose control converged.
Silink M: APEG Handbook on Childhood and Adolescent Diabetes: The Management of Insulin-Dependent (Type 1) Diabetes Mellitus (IDDM). Parramatta NSW: Australasian Paediatric Endocrine Group; 1996.
Swift PGF: ISPAD Guidelines 2000. Zeist: Medical Forum International; 2000. These are the most current, thorough consensus guidelines from the premier international pediatric diabetes society: ISPAD. It is available from the Secretary-General of ISPAD and from the ISPAD website (http://www.ispad.org/) for downloading and printing.
Couper JJ, Staples AJ, Cocciolone R, et al.: Relationship of smoking and albumin excretion in children with IDDM. Diabet Med 1994, 11:666–669.
Kordonouri O, Danne T, Hopfenmuller W, et al.: Lipid profiles and blood pressure: are they risk factors for the development of early background retinopathy and incipient nephropathy in children with insulin-dependent diabetes mellitus? Acta Paediatr 1996, 104:1079–1084.
Chase HP, Garg SK, Jackson WE, et al.: Blood pressure and retinopathy in type 1 diabetes. Ophthalmology 1990, 97:155–159.
Dickey RA: The J-shaped curve for glycosylated hemoglobin. Endocr Pract 1998, 4:174.
Brink SJ, Moltz K: The message of the DCCT for children and adolescents. Diabetes Spectrum 1997, 248–267.
DCCT Research Group: The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the Diabetes Control and Complications Trial. Diabetes 1995, 44:968–983.
Danne T, Weber B, Harman R, et al.: Long-term glycemic control has a nonlinear association to the frequency of background retinopathy in adolescents with diabetes: follow-up of the Berlin Retinopathy Study. Diabetes Care 1994, 17:1390–1396.
Warram JH, Manson JE, Krolewski AS: Glycated hemoglobin and the risk of retinopathy in insulin-dependent diabetes mellitus. N Engl J Med 1995, 332:1305–1306.
Brink SJ: Pubertal and post-pubertal diabetes. In Pediatric and Adolescent Diabetes Mellitus. Edited by Brink SJ. Chicago: Yearbook Medical Publishers; 1987:89–137.
Santiago JV: Medical Management of Insulin-Dependent (Type 1) Diabetes, edn 2. Alexandria: American Diabetes Association; 1994.
American Diabetes Association: Standards of medical care for patients with diabetes mellitus. Diabetes Care 2001, 24(suppl 1):S33-S43.
DCCT Research Group: Color photography versus fluorescein angiography in the detection of diabetic retinopathy in the Diabetes Control and Complications Trial. Arch Ophthalmol 1989, 107:237–243.
Kostraba JN, Dorman JS, Orchard TJ, et al.: Contribution of diabetes duration before puberty to the development of microvascular complications in IDDM subjects. Diabetes Care 1989, 12:686–693.
Dorchy H: What level of HbA1c can be achieved in young patients beyond the honeymoon period? Diabetes Care 1993, 16:1311–1313.
Burger W, Hovener G, Dusterhus R, et al.: Prevalence and development of retinopathy in children and adolescents with type 1 (insulin-dependent) diabetes mellitus: a longitudinal study. Diabetologia 1986, 29:17–22.
McNally PG, Raymond NT, Swift PGF, et al.: Does the prepubertal duration of diabetes influence the onset of microvascular complications? Diabet Med 1993, 10:906–908.
Donaghue KC, King J, Fung ATW, et al.: The effect of prepubertal diabetes duration on diabetes microvascular complications in early and late adolescence. Diabetes Care 1997, 20:77–80.
Daneman D, Drash AL, Lobes LA, et al.: Progressive retinopathy with improved control in diabetic dwarfism (Mauriac syndrome). Diabetes Care 1981, 4:360–365.
Dahl-Jorgensen K, Brinchmann-Hansen O, Hansen KF, et al.: Rapid tightening of blood glucose control leads to transient deterioration in retinopathy in insulin dependent diabetes mellitus-the Oslo Study. BMJ 1985, 290:811–815.
Donaghue K: Retinopathy. In Diabetes and the Adolescent. Edited by Werther GA, Court JM. Melbourne: Miranova Publishers; 1998:157–173.
Klein R, Klein BEK, Moss SE, et al.: The Wisconsin epidemiology study of diabetic retinopathy: II: prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol 1984, 102:520–526.
Krolewski AS, Warram JH, Rand LI, Kahn CR: Epidemiologic approach to the etiology of type 1 diabetes mellitus and its complications. N Engl J Med 1987, 317:1390–1398.
Kostraba JN, Klein R, Dorman JS, et al.: The Epidemiology of Diabetes Complications Study IV: correlates of diabetic background and proliferative retinopathy. Am J Epidemiol 1991, 133:381–391.
Early Treatment Diabetic Retinopathy Study Research Group: Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Ophthalmology 1987, 94:761–774.
Diabetic Retinopathy Study Research Group: Photocoagulation treatment of proliferative diabetic retinopathy: clinical application of Diabetic Retinopathy Study (DRS) findings. Ophthalmology 1981, 88:583–600.
Andersen AR, Christiansen JS, Anderson JK, et al.: Diabetic nephropathy in type 1 (insulin-dependent) diabetes: an epidemiological study. Diabetologia 1983, 25:496–501.
Mogensen CE: Natural history of renal functional abnormalities in human diabetes mellitus: from normoalbuminuria to incipient and overt nephropathy. Contemp Issues Nephrol 1989, 20:19–49.
Couper JJ, Jones TW, Donaghue KC, et al.: The Diabetes Control and Complications Trial: implications for children and adolescents: Australasian Paediatric Endocrine Group. Med J Aust 1995, 162:369–372.
Cruickshanks KJ, Orchard TJ, Becker DJ: The cardiovascular risk profile of adolescents with insulin-dependent diabetes mellitus. Diabetes Care 1985, 8:118–124.
Seaquist E, Goetz F, Rich S, Barbosa J: Familial clustering of diabetic kidney disease. N Engl J Med 1989, 320:1161–1165.
Krolewski AS, Canessa M, Warram JH: Predisposition to hypertension and susceptibility to renal disease in insulin dependent diabetes mellitus. N Engl J Med 1988, 318:140–145.
Laffel LM, McGill JB, Gans DJ: The beneficial effect of angiotensin converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria: North American Microalbuminuria Study Group. Am J Med 1995, 99:497–504.
Cook JJ, Balfe JW, Spino M, et al.: Angiotensin converting enzyme inhibitor therapy decreases microalbuminuria in normotensive children with IDDM. J Pediatr 1990, 117:39–45.
Rudberg S, Aperia A, Freyschuss U, Persson B: Enalapril reduces microalbuminuria in young, normotensive type 1 (insulindependent) diabetic patients irrespective of a hypotensive effect. Diabetologia 1990, 33:470–476.
Mortensen HB, Marinelli K, Norgaard K, et al.: A nationwide cross-sectional study of urinary albumin excretion rate, arterial blood pressure and blood glucose control in Danish children with type 1 diabetes mellitus. Diabet Med 1990, 7:887–897.
Coonrad BA, Ellis D, Becker DJ, et al.: Predictors of microalbuminuria in individuals with IDDM: Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes Care 1993, 16:1376–1383.
Schultz CJ, Neil HAW, Dalton RN, Dunger DB, Oxford Regional Prospective Study Group: Risk of nephropathy can be detected before the onset of microalbuminuria during the early years after diagnosis of type 1 diabetes. Diabetes Care 2000, 23:1811–1815.
Houtman PN, Campbell FM, Shah V, et al.: Sodium-lithium countertransport in children with diabetes and their families. Arch Dis Child 1995, 72:133–136.
Chiarelli F, Casani A, Tumini S, et al.: Diabetic nephropathy in childhood and adolescence. Diabetes Nutr Metab 1999, 12:144–153.
Bojestig M, Arnqvist HJ, Hermansson G, et al.: Declining incidence of nephropathy in insulin dependent diabetes mellitus. N Engl J Med 1994, 330:15–18.
Cooper ME, Allen TJ, Couper J: Nephropathy and hypertension. In Diabetes and the Adolescent. Edited by Werther GA, Court JM. Melbourne: Miranova Publishers; 1998:139–156.
Brodsky IG, Robins DC, Hiser E, et al.: Effects of low protein diet on protein metabolism in insulin dependent diabetes mellitus patients with early nephropathy. J Clin Endocrinol Metab 1992, 75:351–357.
Clarke C: Neuropathy. In Diabetes and the Adolescent. Edited by Werther GA, Court JM. Melbourne: Miranova Publishers; 1998:175–189.
Greene DA, Lattimer SA, Sima AF: Sorbitol, phosphoinositides and sodium-potassium ATPase in the pathogenesis of diabetic complications. N Engl J Med 1987, 316:599–606.
Young RJ, Macintyre CC, Martyn CN, et al.: Progression of subclinical polyneuropathy in young patients with type 1 (insulin-dependent) diabetes: association with glycaemic control and microangiopathy (microvascular complications). Diabetologia 1986, 29:156–161.
Barkai L, Madacsy L, Kassay L: Investigation of subclinical signs of autonomic neuropathy in the early stages of childhood diabetes. Horm Res 1990, 34:54–59.
Becker DJ, Greene DA, Aono SA, et al.: Assessment of subclinical autonomic and peripheral neuropathy in childhood insulin-dependent diabetes mellitus. Pediatr Adolesc Endocrinol 1988, 17:173–178.
Verrotti A, Chiarelli F, Blasetti A, Morgese G: Autonomic neuropathy in diabetic children. J Paediatr Child Health 1995, 31:545–548.
Barkai L, Madacsy L: Cardiovascular autonomic dysfunction in diabetes mellitus. Arch Dis Child 1995, 73:515–518.
DCCT Research Group: Hypoglycemia in the Diabetes Control and Complications Trial. Diabetes 1997, 46:271–286.
Dorchy H: What glycemic control can be achieved in young diabetics without residual secretion of endogenous insulin? What is the frequency of severe hypoglycemia and subclinical complications? Arch Pediatr 1994, 1:970–981.
Nordfeldt S, Ludvigsson J: Severe hypoglycemia in children with IDDM: a prospective population study, 1992-1994. Diabetes Care 1997, 20:497–503.
Brink SJ: Hypoglycaemia in children and adolescents with type 1 diabetes mellitus. Diabetes Nutr Metab 1999, 12:108–121.
Amiel SA, Tamborlane WV, Sacca L, Sherwin RS: Hypoglycemia and glucose counterregulation in normal and insulin-dependent diabetic subjects. Diabetes Metab Rev 1988, 4:71–89.
Cryer PE: Iatrogenic hypoglycemia as a cause of hypoglycemia- associated autonomic failure in IDDM: a vicious cycle. Diabetes 1992, 41:255–260.
Cryer PE, Fisher JN, Shamoon H: Hypoglycemia. Diabetes Care 1994, 17:734–755.
White NH, Skor DA, Cryer PE, et al.: Identification of type 1 diabetic patients at increased risk for hypoglycemia during intensive therapy. N Engl J Med 1983, 308:485–491.
Gibson LC, Halvorson MJ, Carpenter S, Kaufman FR: Short-term use of the Minimed continuous monitoring system to determine patterns of glycemia in pediatric patients with type 1 DM. Diabetes 2000, 6(suppl 1):1664.
Sovik O: Dead-in-bed syndrome in young diabetic patients. Diabetes Care 1999, 22:B40-B42.
White N, Waltman S, Krupi T, Santiago J: Reversal of neuropathic and gastrointestinal complications related to diabetes mellitus in adolescents with improved metabolic control. J Pediatr 1981, 99:41–45.
Brown M, Ahmed ML, Clayton K, Dunger DB: Growth during childhood and final height in type 1 diabetes. Diabet Med 1994, 11:182–187.
Clarke WL, Vance ML, Rogol AD: Growth and the child with diabetes mellitus. Diabetes Care 1993, 16:101–106.
Kjaer K, Hagen C, Sando SH, et al.: Epidemiology of menarche and menstrual disturbances in an unselected group of women with insulin-dependent diabetes mellitus compared to controls. J Clin Endocrinol Metab 1992, 75:524–529.
Adcock CJ, Perry LA, Lindsell AM, et al.: Menstrual irregularities are more common in adolescents with type 1 diabetes: association with poor glycemic control and weight gain. Diabet Med 1994, 11:465–470.
Brink SJ: Limited joint mobility (LJM). In Pediatric and Adolescent Diabetes Mellitus. Edited by Brink SJ. Chicago: Yearbook Medical Publishers; 1987:305–312.
Rosenbloom AL: Skeletal and joint manifestation of childhood diabetes. Pediatr Clin North Am 1984, 31:569–589.
Brownlee M: Glycation and diabetic complications. Diabetes 1994, 43:836–884.
Batch JA: Growth and puberty. In Diabetes and the Adolescent. Edited by Werther GA, Court JM. Melbourne: Miranova Publishers; 1998:93–112.
Mauriac P: Hepatomegalies de l’enfance avec troubles de la croissance et du metabolisms des glucides [in French]. Paris Med 1934, 2:525–528.
Becker DJ: Complications of IDDM in childhood and adolescence. In Pediatric Endocrinology, edn 3. Edited by Lifshitz F. New York: Marcel Dekker; 1996:585.
Brink SJ: Thyroid dysfunction in youngsters with IDDM. J Pediatr Endocrinol 1985, 1:181–184.
Pocecco M, Ventura A: Coeliac disease and insulin dependent diabetes mellitus: a causal association? Acta Paediatr 1995, 84:1432–1434.
Carlsson A, Axelsson IE, Borulf SK, et al.: Prevalence of IgAantiendomysium and IgA-antigliadin autoantibodies at diagnosis of insulin-dependent diabetes mellitus in Swedish children and adolescents. Pediatr 1999, 103:1248–1252.
Kelly WF, Nicholas J, Adams J, Mahmood R: Necrobiosis lipoidica diabeticorum: association with background retinopathy, smoking and proteinuria: a case control study. Diabet Med 1993, 10:725–728.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Brink, S.J. Complications of pediatric and adolescent type 1 diabetes mellitus. Curr Diab Rep 1, 47–55 (2001). https://doi.org/10.1007/s11892-001-0010-1
Issue Date:
DOI: https://doi.org/10.1007/s11892-001-0010-1